SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of...
Hence then, the article about carsgen announces data of allogeneic bcma car t cell therapy ct0596 for relapsed refractory multiple myeloma at the 2025 ash annual meeting was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting )
Also on site :
- Stunning ISS Photo of Florida, Cuba Captures & 039;Moonglint& 039;
- A Shockingly Recent Year Just Cracked the Top 5 of Rock's Most Legendary Years
- Saudi-led coalition strikes Yemeni port over unauthorised weapons shipment